Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
about
Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challengesNeuropathic low back pain in clinical practice[Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy].Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.Successful use of stellate ganglion block and a new centrally acting analgesic with dual mode of action in a resistant temporomandibular joint painReady conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended releaseDriving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial.Combining opioid and adrenergic mechanisms for chronic pain.Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patientsA pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathyLasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain.Neuropathic Pain and Spinal Cord Injury: Phenotypes and Pharmacological Management.Prediction of response to tapentadol in chronic low back pain.A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.Tapentadol extended release for the management of chronic neck pain.Tapentadol extended release for chronic pain patients.World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction.Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.Evaluation and Management of SCI-Associated Pain.Unique pharmacology of tapentadol for treating acute and chronic pain.Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.Palmitoylethanolamide in the Treatment of Failed Back Surgery SyndromeAssessment and manifestation of central sensitisation across different chronic pain conditions.Tapentadol in neuropathic pain cancer patients: a prospective open label study.Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.Tapentadol versus tramadol in the management of low back pain in the emergency department: Impact of use on the need for reassessments.Osteoarthritis pain: nociceptive or neuropathic?Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain.Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study
P2860
Q24627422-6A7A8ADE-1A0E-488C-AB79-7D8AC0C52EB5Q28073412-7FCAF983-1E6A-481A-8591-B7D3750EB16EQ30959153-C9C3A3B1-E76E-456C-ABF1-744CEC81363CQ31128284-6EDDC0DC-6577-4B93-82DA-66817843C309Q33691651-A70D0E8F-F064-4882-B0FB-4FE3BFCD0333Q33775071-4CD89D03-BDA6-479C-8901-7974DCE02382Q33938745-201EAB35-77E4-4FE1-BF82-BBFE0DED947AQ34434307-ED9DDA79-C16C-4975-83C8-0403B70307AEQ34783638-CA2C4382-9466-40AC-AE28-C4F29CCBF964Q34990241-40AF84C8-4F0E-4536-A487-295111138D83Q35752535-01741692-721D-4C5E-940E-BE7F3E44BCD3Q36357469-B263D409-9339-419C-9ABE-C1F2D73199AEQ37596022-8570B250-F911-4558-A27E-D7401F8C9E61Q37653402-5EA5208D-F3F9-492F-8077-738A9E9568A5Q37682809-80DD8C37-8C1E-42E8-9769-018C99D065DCQ38074832-143323C2-E7E6-4448-BF44-C0E0C89C13ACQ38646237-121DAB4B-6FA8-4AEE-8963-4928E248A77FQ38827493-955FFCB0-0546-45A0-BAAC-5632B56E5600Q38913057-1B2A89E0-A771-4444-B319-F136A00FF75AQ38980690-EB3367CB-7BDF-44C2-8525-149B6992411FQ39208211-B29F8D69-5DA9-4A78-8560-D04BA9454A15Q39221988-B612B917-8E92-4BD7-9FDA-ED07F56228CFQ39230971-ED150DD1-B67B-4558-9C84-B87BB8312706Q41508796-75F1AC46-6D44-49FD-B34C-ABEB1A016940Q47234803-2F58AF6F-4DF2-4CDE-8C28-F6F1F5C3B02CQ47324314-8293D25B-1C2E-4D65-AB3F-20A4C2A39AA6Q47914794-7452EDD2-9CB6-4495-AB49-A8FD11AEAF69Q49774887-88CEAD49-56FF-4719-8B0F-7234143011D2Q51098399-EB0D4B58-A2E8-46BB-8FA5-2DA0ACFEBAEAQ52603231-07A802A6-EBAC-411A-B0A1-118750703ED2Q58749196-60AD5C1E-D3F6-4D51-BCFA-D217C3F97D40Q58912037-BA03BEDD-8A65-4D29-B17D-75AEBAC90DEC
P2860
Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@ast
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@en
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@nl
type
label
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@ast
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@en
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@nl
prefLabel
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@ast
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@en
Effectiveness and safety of ta ...... an open-label, phase 3b study.
@nl
P2093
P921
P1476
Effectiveness and safety of ta ...... an open-label, phase 3b study
@en
P2093
Anthony Davies
Antonio Gatti
Daniel Samper
Hans G Kress
Ilona Steigerwald
Matthias Müller
Ralf Baron
Sylvie Rozenberg
P304
P356
10.1185/03007995.2012.679254
P407
P577
2012-05-09T00:00:00Z